Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications

Abstract

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and / or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.

Description

CROSS REFERENCE TO RELATED APPLICATION[0001]This application claims the benefit under 35 U.S.C. 119(e) of U.S. Provisional Patent Application No. 61 / 149,593 filed Feb. 3, 2009, which is incorporated herein by reference in its entirety.BACKGROUND[0002]1. Technical Field[0003]The presently disclosed invention embodiments relate to compositions and methods for the treatment of microbial infections. In particular, the present embodiments relate to improved treatments for managing bacterial infections in epithelial tissues, including in wounds such as chronic wounds and acute wounds, and including treatment of bacterial biofilms and other conditions.[0004]2. Description of the Related Art[0005]The complex series of coordinated cellular and molecular interactions that contribute to skin wound healing, and / or to healing or maintenance of epithelial tissues generally, may be adversely impacted by a variety of external factors, such as opportunistic and nosocomial infections (e.g., clinical ...

AI Technical Summary

Benefits of technology

The patent describes using bismuth-thiol compounds as antiseptic agents to treat acute, chronic, and bacterial biofilm wounds. These compounds can reduce the number of people affected by such wounds and decrease the cost of treatment. The patent also discusses a new method of making these compounds and a topical formulation that combines them with antibiotics to provide unprecedented antibacterial effects, including against biofilms. The method includes making monodisperse microparticulate suspensions of bismuth-thiol.

Problems solved by technology

The complex series of coordinated cellular and molecular interactions that contribute to skin wound healing, and / or to healing or maintenance of epithelial tissues generally, may be adversely impacted by a variety of external factors, such as opportunistic and nosocomial infections (e.g., clinical regimens that can increase the risk of infection), local or systemic administration of antibiotics (which may influence cell growth, migration or other functions and can also select for antibiotic-resistant microbes), frequent wound dressing changes, open-air exposure of wounds to speed healing, the use of temporary artificial structural support matrix or scaffold materials, and / or the possible need for debridement and / or repeat surgery to excise infected or necrotic tissue.

Wound healing thus continues to be a formidable challenge for clinical practitioners worldwide.

The current treatments for recalcitrant wounds are impractical and ineffective, often requiring multiple surgeries to close the wound.

For instance, Regranex® (becaplermin, Ortho-McNeil Pharmaceutical, Inc., available from Ethicon, Inc., recombinant platelet-derived growth factor) exemplifies one of the few available treatments for chronic wounds, but is expensive to produce and has limited clinical utility.

Chronic wounds may become very painful and stressful for the patient when nearby nerves become damaged (neuropathy) as the wound progresses.

These wounds affect four million Americans each year and cost about $9 billion in treatment expenses.

Pressure ulcers may be present when local pressure that is exerted at or around a wound site is greater than blood pressure, for instance, such that poor circulation, paralysis, and / or bed sores may contribute to, or exacerbate, the chronic wound.

Diabetic ulcers may occur in individuals with diabetes mellitus, for example, persons in whom uncontrolled high blood sugar can contribute to a loss of feeling in the extremities, leading to repetitive injuries and / or neglect on the part of the individual to attend to injuries.

In the case of epithelial tissues in the respiratory and / or gastrointestinal tracts, inaccessibility, occlusion, difficulty in generating epithelial surface-clearing fluid forces or development of localized microenvironments conducive to microbial survival can engender clinical complications.

Any or all of these events, and especially infection, can delay or prevent the effective tissue repair processes that are involved in wound healing.

These products, however, are not designed to address the problem of bacterial tissue infiltration and wound spreading.

Unfortunately, systemic antibiotics are not effective for the treatment of chronic wounds, and are generally not used unless an acute infection is also present.

Current approaches to the treatment of chronic wounds include application of topical antibiotics, but such remedies may promote the advent of antibiotic-resistant bacterial strains and / or may be ineffective against bacterial biofilms.

There are many antiseptics widely in use, but bacterial populations or subpopulations that are established in some chronic wounds may not respond to these agents, or to any other currently available treatments, thus requiring surgical amputation or resection to prevent further spread of the infection within the host, i.e., the undesirable loss of an infected limb or other tissue.

Additionally, a number of antiseptics may be toxic to host cells at the concentrations that may be needed to be effective against an established bacterial infection at a chronic wound site, and hence such antiseptics are unsuitable.

Particularly problematic are infections composed of bacterial biofilms, a relatively recently recognized organization of bacteria by which free, single-celled (“planktonic”) bacteria assemble by intercellular adhesion into organized, multi-cellular communities (biofilms) having markedly different patterns of behavior, gene expression, and susceptibility to environmental agents including antibiotics.

Recent research has shown that open wounds can quickly become contaminated by biofilms.

These microbial biofilms are thought to delay wound healing, and are very likely related to the establishment of serious wound infections.

While this early intervention is important, it is not adequate to prevent the development of infection.

Because of the complex nature of military traumatic wounds, the potential for infection is great, particularly considering the introduction of foreign objects and other environmental contaminating agents.

Acute and chronic wounds, including surgical and military wounds, have already compromised the body's primary defense and barrier against infection; the skin.

Infection of wounds in hospitals constitutes one of the most common causes of nosocomial infection, and wounds acquired in military and natural disaster environments are particularly susceptible to microbial contamination.

Military wounds are predisposed to infection because they are typically associated with tissue damage, tend to be extensive and deep, may introduce foreign bodies and interfere with local blood supply, may be associated with fractures and burns, and may lead to shock and compromised immune defenses.

Pigmented melanocytes in the basal layer absorb potentially harmful ultraviolet (UV) radiation.

Disruption of the skin presents undesirable risks to a subject, including those associated with opportunistic infections, incomplete or inappropriate tissue remodeling, scarring, impaired mobility, pain and / or other complications.

Like the skin, other epithelial surfaces (e.g., respiratory tract, gastrointestinal tract and glandular linings) have defined structural attributes when healthy such that infection or other disruptions may present serious health risks.

Damaged or broken skin may result, for example, from wounds such as cuts, scrapes, abrasions, punctures, burns (including chemical burns), infections, temperature extremes, incisions (e.g., surgical incisions), trauma and other injuries.

Although skin naturally exhibits remarkable ability for self-repair following many types of damage, there remain a number of contexts in which skin healing does not occur rapidly enough and / or in which inappropriate cellular tissue repair mechanisms result in incompletely remodeled skin that as a consequence can lack the integrity, barrier properties, mechanical strength, elasticity, flexibility, or other desirable properties of undamaged skin.

Skin wound healing thus presents such associated challenges, for example, in the context of chronic wounds.

Bismuth by itself may not be therapeutically useful and may exhibit certain inappropriate properties, and so may instead be typically administered by means of delivery with a complexing agent, carrier, and / or other vehicle, the most common example of which is Pepto Bismol®, in which bismuth is combined (chelated) with subsalicylate.

Despite the availability of BT compounds for well over a decade, effective selection of appropriate BT compounds for particular infectious disease indications has remained an elusive goal, where behavior of a particular BT against a particular microorganism cannot be predicted, where synergistic activity of a particular BT and a particular antibiotic against a particular microorganism cannot be predicted, where BT effects in vitro may not always predict BT effects in vivo, and where BT effects against planktonic (single-cell) microbial populations may not be predictive of BT effects against microbial communities, such as bacteria organized into a biofilm.

Additionally, limitations in solubility, tissue permeability, bioavailability, biodistribution and the like may in the cases of some BT compounds hinder the ability to deliver clinical benefit safely and effectively.

Images